Highlights
The API ADAD Colombia trial investigated whether crenezumab, an anti-amyloid monoclonal antibody, could delay cognitive decline in a unique cohort of individuals genetically predisposed to early-onset Alzheimer’s disease. Despite a robust 5-to-8-year treatment period, the study found no statistically significant difference between the crenezumab and placebo groups regarding the annualized rate of change in cognitive scores. Furthermore, the treatment did not demonstrate a significant impact on amyloid plaque removal or other key biomarkers, reinforcing the hypothesis that high-affinity fibrillar amyloid clearance may be a prerequisite for clinical efficacy.
